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Purpose. To evaluate the pharmacological activity of insulin-loaded alginate/chitosan nanoparticles
following oral dosage in diabetic rats.
Methods. Nanoparticles were prepared by ionotropic pre-gelation of an alginate core followed by
chitosan polyelectrolyte complexation. In vivo activity was evaluated by measuring the decrease in blood
glucose concentrations in streptozotocin induced, diabetic rats after oral administration and flourescein
(FITC)-labelled insulin tracked by confocal microscopy.
Results. Nanoparticles were negatively charged and had a mean size of 750 nm, suitable for uptake
within the gastrointestinal tract due to their nanosize range and mucoadhesive properties. The insulin
association efficiency was over 70% and insulin was released in a pH-dependent manner under simulated
gastrointestinal conditions. Orally delivered nanoparticles lowered basal serum glucose levels by more
than 40% with 50 and 100 IU/kg doses sustaining hypoglycemia for over 18 h. Pharmacological
availability was 6.8 and 3.4% for the 50 and 100 IU/kg doses respectively, a significant increase over
1.6%, determined for oral insulin alone in solution and over other related studies at the same dose levels.
Confocal microscopic examinations of FITC-labelled insulin nanoparticles showed clear adhesion to rat
intestinal epithelium, and internalization of insulin within the intestinal mucosa.
Conclusion. The results indicate that the encapsulation of insulin into mucoadhesive nanoparticles was a
key factor in the improvement of its oral absorption and oral bioactivity.
KEY WORDS: hypoglycemic effect; insulin; nanoparticle; natural polymers; oral delivery.
INTRODUCTION
Among controlled release formulations, polymeric nano
and microparticles have shown interesting promise for
protein delivery (1). Nanoparticulate hydrogels consisting of
alginate, agar, agarose, chitosan, or synthetic polymers have
been developed and tested over the past two decades (2,3).
Nanoparticulate delivery systems have the potential to
improve protein stability, increase the duration of the
therapeutic effect and permit administration through non-
parental routes (4).
Oral delivery is the preferred route for administration
because it is non-invasive, avoids injections, and decreases
risk of infection. It is also physiologically desirable, since the
exogenous protein imitates the physiological pathway under-
going first hepatic bypass. The intestinal absorption of
proteins has been reported and a combination of mechanisms
described to explain how proteins cross the intestinal mucosa.
One approach to improve the gastrointestinal uptake of
poorly absorbable drugs like insulin is to entrap the protein
within colloidal nanoparticles, which provide degradative
protection in the gastrointestinal tract and facilitate transport
into systemic circulation (2,5). Special attention has been
given to mucoadhesive particles which maintain contact with
intestinal epithelium for extended periods, promoting pene-
tration of active drug through and between cells due to the
concentration gradient between nanoparticles and intestinal
membrane. In fact, insulin was observed to be directly
internalized by enterocytes in contact with intestine (6,7),
and retention of drugs at their absorptive sites by mucoadhe-
sive carriers is a synergic factor. Furthermore, uptake of
nanoparticles by the M cells of the Peyer_s patches was
demonstrated, being absorbed transcellularly, serving as a
major gateway for nanoparticle absorption (8–10) as well as
absorption through the much more numerous gut enterocytes
(11). Endocytosis occurs through clathrin coated pits and
vesicles, fluid phase endocytosis and phagocytosis (12). It is
well accepted that hydrophobic, negatively charged, protein-
loaded nanoparticles smaller that 1 mm potentially show the
best absorption rate (13,14), although other factors may
govern nanoparticle absorption.
Polymers such as alginate and chitosan have been
described as biocompatible, biodegradable and mucoadhe-
sive, enabling numerous pharmaceutical and biomedical
applications (15–18) including the design of controlled
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release devices. Alginate (Alg) is an anionic polysaccharide
of (1–4)-linked b-D-mannuronic acid (M) and a-L-guluronic
acid (G) widely used in bioencapsulation of drugs, proteins
and cells. The gelling properties of its guluronic residues with
divalent ions such as calcium permit the formation of Alg
matrices for gels, films, beads, pellets, microparticles and
nanoparticles. Chitosan (Chit) is the cationic deacetylated
form of chitin [poly-b-(1–4)-N-acetyl-D-glucosamine],
obtained from exoskeletons of marine arthropods. Chitosan
is of interest for a nanoparticulate oral delivery vehicle
because it is able to reduce the transepithelial electrical
resistance and transiently opening tight conjunction between
epithelial cells (19). A variety of Chit-based colloidal delivery
vehicles have been described for the association and delivery
of drugs (20). We have recently described the nanoencapsu-
lation of insulin in Alg by inducing the ionotropic pre-
gelation of a dilute aqueous Alg solution with calcium
chloride. Chit then formed a polyelectrolyte complex with
alginate (21). Alg/Chit nanoparticles were designed for
protection from the aggressive environment of the stomach
when administered orally. Insulin was partially retained in a
gastric pH environment for up to 24 h while a more extensive
release was observed under intestinal pH simulation (21).
Proteins are often unstable and consequently easily
damaged during formulation in pharmaceutical dosage forms
(22). Insulin-loaded nanoparticles are formulated with or-
ganic solvents which are potentially harsh and may denature
proteins (23–25). However, ionotropic pre-gelation did not
induce conformational changes to the insulin structure in
terms of a-helix and b-sheet content (26).
The objectives of the present study were to determine
whether the nanoparticulate formulation induced a hypogly-
cemic effect after oral administration to diabetic rats, and to
examine the mechanism of insulin absorption from the GI
tract. The rat model was chosen due to its similitude to
human and wide acceptance for evaluating the effectiveness
of an oral dosage for of insulin, in comparison to other
animal models (27–29).
MATERIALS
Low-guluronic content, low viscosity sodium Alg, low
molecular weight Chit ($50 KDa) and calcium chloride were
purchased from Sigma (Portugal). Polyanion stock solutions
were prepared in deionized water (Milli-Q) overnight under
magnetic stirring and Chit samples were dissolved in 1%
acetic acid solution in deionized water followed by filtering
using a Millipore #2 paper filter and stored at 4-C.
Recombinant human crystalline zinc-insulin was a gift from
Lilly Portugal. Wistar male rats weighing 200–250 g, were
provided by Charles River, Barcelona, Spain. Streptozocin
and insulin-flourescein (FITC) from bovine pancreas were
from Fluka (Sigma, Portugal). Alexa Fluor 594 conjugate was
from Molecular Probes (Oregon, USA). Human insulin
detecting ELISA kit (HIEZ 126) was from Linco (Missouri,
USA).
Preparation of Nanoparticles
Nanoparticles were prepared from dilute Alg solution
containing insulin by inducing an ionotropic pre-gel with
calcium counter ions, followed by polyelectrolyte complex
coating with Chit, as described previously (21). Particle
sizes below 1,000 nm were obtained with 0.05% (w/w) Alg,
0.9 mM of Ca2+ and 0.012% (w/w) Chit. The pH of Alg and Chit
solutions was adjusted to 4.9 and 4.6, respectively. Nanoparticles
were recovered by centrifugation (20,000g/30 min).
Nanoparticle Characterization
Particle size was determined by photon correlation
spectroscopy at 25-C with a detection angle of 90- and zeta
potential by laser doppler anemometry by using a Malvern
Zetasizer and Particle Analyzer 5000 (Malvern Instruments).
Measurements were made on aqueous dilute nanoparticle
suspension (n Q 6).
The association efficiency (AE) was determined by
calculating the difference between the total amount used to
prepare the particles and the amount of insulin present in the
supernatant after nanoparticle removal by centrifugation. The
difference between the total insulin initially used to prepare
the particles and the amount of residual unassociated insulin
after particle separation as a percent of total nanoparticle dry
mass is referred to as loading capacity (LC). Insulin was
measured by high-performance liquid chromatography
(HPLC).
Insulin In Vitro Release from Nanoparticles
Insulin-loaded nanoparticles (200 mg) were placed into
20 ml of HCl buffer at pH 1.2 (USP XXVIII) and incubated
at 37-C for 2 h. At determined times, 0.4 ml of supernatant
was taken, separated from nanoparticles by centrifugation
(20,000g/30 min) for insulin determination and replaced by
fresh medium. After 2 h, the nanoparticles were transferred
to 20 ml of phosphate buffer at pH 6.8 (USP XXVIII) and
incubated at 37-C for an additional 4 h. At determined times,
0.4 ml of supernatant was taken, separated from nano-
particles by centrifugation (20,000g/30 min) for insulin
determination and replaced by fresh medium. Release assays
were performed in triplicate. Insulin was measured by HPLC.
Insulin Determination
Insulin was determined by HPLC as described in detail
previously (30) using a solvent delivery system (Varian 9012)
Table I. Characterization of Alg/Chit Nanoparticles in Terms of Mean Size, Zeta Potential, Insulin AE and LC (n = 3, Mean T SD)
Size (nm) Zeta Potential (mV) AE (%) LC (%)
Insulin-loaded nanoparticles 748 T 217 j5.6 T 1.9 72.8 T 2.1 9.9 T 1.5
Unloaded nanoparticles 781 T 61 j14.5 T 2.09 – –
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and l = 214 nm detector (Varian 9050) equipped with an
XTerra RP 18 column, in a gradient method. Time of run was
10 min and eluents were 0.1% trifluoracetic acid aqueous
solution and acetonitrile initially set in a 70/30 ratio and
linear gradient to 60/40 over 5 min. From 5 to 10 min, ratio
was kept constant at 60/40. Final insulin concentrations were
calculated with the Varian Star Workstation software against
a calibration curve. All measurements were made in triplicate.
In Vivo Pharmacological Activity
Animals were maintained in accordance with the
Federation of European Laboratory Animal Science Asso-
ciation and the European Union (Council Directive 86/609/
EEC). Male Wistar rats with 250–300 g were housed in cages
under controlled temperature and humidity, and fed a
laboratory animal standard diet feed (Mucedola Top Certif-
icate, Italy) and provided tap water ad libitum. Lighting was
on a 12 h on /12 h off cycle. Rats were rendered diabetic by a
single intraperitoneal injection of streptozocin (50 mg/mL in
pH 4.5 citrate) at 50 mg/kg. After 2 weeks, rats with fasted
blood glucose levels above 250 mg/dL were randomly grouped
(n = 6) and used for experiments. These rats were fasted
12 h before and 24 h during the experiment, but were allowed
water ad libitum. Test samples (1.0 mL) were administered
intragastrically by gavage and blood samples (0.2 mL)
collected from the tail vein. Sample was separated in two
volumes, one to determine plasma glucose level and the other
for insulin determination. For insulin determination, serum
was separated from the blood samples by centrifugation (5,000
rpm for 10 min) and stored at j80-C until analysis.
Rats were divided into seven groups. Nanoparticles were
administered at insulin doses of 25, 50 and 100 IU/kg. Control
rats were similarly administered with equivalent volumes of
an insulin solution (50 IU/kg), a solution of insulin (50 IU/kg)
and empty nanoparticles, or a dispersion of blank nano-
particles. The volume of dispersion and controls administered
was 1.0 mL. Also, a control using subcutaneously injected
insulin (2.5 IU/kg) was used. Aliquots were collected before
and during 24 h period following administration.
Plasma glucose levels were plotted against time to
evaluate the cumulative hypoglycemic effect over time after
insulin administration, quantified by the area above the
curve, determined using the trapezoidal method. Pharmaco-
logical availability (PA) of peroral insulin loaded into nano-
particles and in solution were determined as the relative
measure of the cumulative reduction in glucose blood levels
compared to a 100% availability of the control insulin
administered subcutaneously at a dose of 2.5 IU/kg. Plasma
insulin levels were plotted against time to evaluate the
cumulative amount of insulin delivered to the plasma after
insulin administration, quantified by area under the curve.
The cumulative hypoglycemic effect and the cumulative
amount of insulin delivered to plasma were calculated for
each rat, and a one-way analysis of variance (ANOVA) used
to evaluate treatment differences. If the group by each time
interaction was significantly different (p < 0.05), differences
between groups were compared within a post-hoc test
(S-N-K). All statistical analyses were performed with the
SPSS software package (SPSS for Windows 14.0, SPSS,
Chicago, USA).
Plasma glucose level was determined using the Medisense
Precision Xceed Kit, (Abbot, Portugal, range 10–600 mg/dL),
and expressed as a percent of the baseline plasma glucose
level. Serum insulin concentration was measured by a solid
two-side enzyme immunoassay (ELISA test kit, Mercodia,
Uppsala, Sweden) based on the direct sandwich technique in
which two monoclonal antibodies are directed against sepa-
rate antigenic determinants on the insulin molecule. Serum
was separated from blood by centrifugation at 5,000 rpm for
10 min and then 25 mL of sample added to each well of a 96
well microplate using the manufacture_s protocol and reading
spectroscopically at 450 nm. Results are shown as the mean
(TSD) of at least 6 animals.
Tracking FITC-Labelled Nanoparticles
FITC labelled insulin was loaded into nanoparticles to
yield 2.0 mg FITC-insulin/mL of nanoparticle suspension and
administered by oral gavage to Wistar diabetic rats fasted
overnight. The rats were sacrificed 3 h later and intestinal
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Fig. 1. Insulin release from Alg/Chit nanoparticles produced with
Alg/Chit mass ratio of 4.3:1 in gastric pH 1.2 simulated fluid for
120 min followed by 240 min intestinal pH 6.8 simulated fluid at 37-C
(n = 3, mean T SD).
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Fig. 2. Plasma glucose levels after administration of insulin-loaded
25 (black circles), 50 (black triangles) and 100 (black squares) IU/kg
and empty nanoparticles (white squares), compared to 2.5 IU/kg
delivered sub-cutaneously (white triangles). Data represents the
mean T SEM, n = 6 per group. Single asterisks 50 IU/kg and double
asterisks 100 IU/kg dose showed statistically significant differences
from negative empty nanoparticle control (p < 0.05).
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segments localized after laparotomy. After washing with
isotonic saline, intestine segments were isolated, filled inside
with Alexa Fluor 594 solution (0.05% in PBS:glycerol 1:1)
and intestinal epithelial cell membranes were stained for 1 h.
Tissue was then rinsed, mounted on glass slides and
immediately observed using a confocal laser scanning micro-
scope (Leica). Tissue samples were scanned in the x,y plane
with a z-step of 500 nm. Since the spectra are not over-
lapping, FITC-insulin and Alexa Fluor could be analyzed
simultaneously with 488 and 561 nm laser respectively.
Control rats were dosed with FITC-insulin solution or empty
nanoparticles.
RESULTS AND DISCUSSION
Nanoparticles produced by ionotropic pre-gelation of
alginate followed by chitosan polyelectrolyte complexation
had mean diameter of approximately 750 nm for both insulin-
loaded and blank nanoparticles as seen in Table I. Particles
with diameters below 1,000 nm are desirable as they are
better absorbed in the intestinal tract (11). Zeta potential
increased from j14.5 to j5.6 mV with the addition of
positively charged insulin, which may partial deposit on the
nanoparticle surface. Insulin AE and LC were 72.8 and 9.9%
respectively. Previously it was shown that physical proper-
ties of Alg/Chit nanoparticles, namely particle size and to a
lesser extent AE, were mainly influenced by the Alg/Chit
mass ratio (21). Alg/Chit mass ratio of 4.3:1 was selected in
the present work with the goal of obtaining a high level of
AE and sub-micro particles since additional chitosan mass
resulted in increased mean particle size and particle
aggregation.
The release of insulin from nanoparticles under gastric
followed by intestinal simulated pH conditions was investi-
gated. The release profile in Fig. 1 was characterized by an
initial rapid release within the first 15 min followed by a
plateau state. After 2 h, 45% of the insulin was released.
Nanoparticles were then transferred to pH 6.8 buffer
simulating intestinal conditions and release was sustained to
70% of the initial amount. The observed immediate release
of insulin at pH 1.2 may be related to release from the
nanoparticle surface, due to the weak interaction forces
between the polyelectrolytes and the protein. However,
insulin entrapped within the matrix faced an additional
physical barrier. Further gastric protection against insulin
release can be attributed to the more effective retention by a
tight Alg network that forms at low pH (31,32). At pH 6.8,
Alg swells as it forms an ionic state, contributing to a higher
amount of insulin release.
The pharmacological effect of insulin loaded nanopar-
ticles was evaluated in diabetic rats dosed orally at loading
levels of 25, 50 and 100 IU/kg. Changes in plasma glucose
compared to those dosed subcutaneously at 2.5 IU/kg and
with empty nanoparticles are shown in Fig. 2. A significant
difference in plasma glucose reduction between insulin-
loaded and empty nanoparticles was observed, especially
8 to 14 h after administration (p < 0.05).
At an insulin dose of 100 IU/kg, a faster onset of action
was elicited compared with doses of 25 or 50 IU/kg. The
reduction in blood glucose was less in the animals receiving
the dose of 25 IU/kg compared with those dosed with 50 and
100 IU/kg. However, the overall plasma glucose levels were
similar for doses of 50 and 100 IU/kg. In addition, these
higher two dose levels resulted in similar values of cumula-
tive hypoglycemic effect, and similar minimum blood glucose
(55% of basal level), as seen in Table II. A dose–response
effect was observed between 25 and 50 IU/kg but absent
between 50 and 100 IU/kg, which may be due to saturation of
the insulin absorption sites at 50 IU/kg. The reduction in
blood glucose was less for animals receiving 25 IU/kg, which
could indicate that the level of absorption saturation had not
been reached. The absence of hypoglycemic effect after
administration of empty nanoparticles confirms that the
Table II. Pharmacodynamic Parameters After Oral Administration of Insulin-Loaded Nanoparticles in 25, 50 and 100 IU/kg Doses and
Insulin Solution 50 IU/kg
Hypoglycemic Effect (%) PA (%) Tmax (h) Cmin (% basal glucose)
Insulin-loaded nanoparticles (25 IU/kg) 19.9 T 5.5 7.1 T 1.7a 8 75.7 T 1.0
Insulin-loaded nanoparticles (50 IU/kg) 27.1 T 6.7a 6.8 T 1.7a 14 58.8 T 5.4a
Insulin-loaded nanoparticles (100 IU/kg) 27.4 T 8.9a 3.4 T 1.7 14 55.2 T 5.5a
Oral solution (50 IU/kg) 10.8 T 1.6 1.6 T 0.7 6 80.8 T 8.3
Data represents the mean T SD, n = 6 per group
Tmax = time at minimum relative basal glucose concentration in the blood, Cmin = minimum relative basal glucose concentration in the blood
a Statistically significant differences from oral insulin solution control (p < 0.05). Hypoglycemic effect determined based on the area above the
curve
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Fig. 3. Plasma glucose levels after oral administration of insulin-loaded
nanoparticles 50 IU/kg (black triangles), oral insulin solution 50 IU/kg
(white triangles), empty nanoparticles (white squares) and physical
mixture of empty nanoparticles and insulin solution 50 IU/kg (white
circles). Data represents the mean T SEM, n = 6 per group.
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decrease of blood glucose levels was exclusively due to the
physiologic effect of insulin.
To investigate whether nanoparticles enabled intestinal
absorption of free insulin, diabetic rats were administered a
suspension of empty nanoparticles in insulin solution (50 IU/
kg), and comparisons drawn to a group administered insulin
solution alone (50 IU/kg). As observed in Fig. 3, both groups
showed small hypoglycemic effects between 2 and 8 h after
administration. However, this effect appeared sooner and
was minor compared to the hypoglycemic effect of the
insulin-loaded nanoparticles. A small fraction of the insulin
could be absorbed through the intestinal wall exerting a
hypoglycaemic effect as observed by others (33,34). In fact, a
small amount of human insulin after oral solution adminis-
tration was detected in the blood by ELISA (Fig. 4),
indicating that it was directly absorbed. The direct uptake
of insulin has been attributed to specific insulin receptors in
intestinal enterocytes (6,7) and rapid internalization by the
epithelial cells to the interstitial space from which it reached
the blood circulation. The upper intestinal area seems to be
the most active region for insulin absorption (35), improved
under fasting conditions (36). The observed and prolonged
hypoglycemic effect of insulin-loaded nanoparticles com-
pared to the minor effect in animals treated with oral insulin
solution leads to the conclusion that Alg/Chit nanoparticles
were to some extent able to stabilize and protect entrapped
insulin from degradation in the gastrointestinal track. The
overall variability of the results obtained was closely similar
to other comparable studies (33,34,37) and mainly due to the
intrinsic intraspecies variability.
The presence of empty Alg/Chit nanoparticles did not
enhance the minor hypoglycemic effect of oral insulin
solution, and therefore did not act as insulin absorption
enhancer. Only the encapsulation of insulin into nanopar-
ticles and the resulting protective effect enabled nanoparti-
culate delivery producing a biological response.
It was also observed previously that the physiologic
effect of orally dosed insulin encapsulated in Chit mucoad-
hesive nanoparticles (33,38), and of antitubercular drugs
encapsulated in Alg/Chit nanoparticles (39) appeared later
than the effect obtained after free drug oral administration.
Also, the relative bioavailabilities were significantly higher
compared with oral free drug solution, consistent with the
results obtained in this study. However, the formulation
developed in the present study was able to prolong the
hypoglycemic effect of insulin for up to 24 h compared with
nanoparticles exclusively composed by Chit where the
hypoglycemic effect was observed for less than 12 h (38) or
in lower extent (33). The presence of a core material
composed of counter-charged Alg, complexed with a shell
material of chitosan, may improve nanoparticle stability
better retaining insulin within the nanoparticle matrix. Thus,
the presence of an Alg core might explain the improved
physiologic effect by increasing two-fold the PA from 4%
obtained for Chit nanoparticles (33) to 7% found in the
present work.
Serum insulin levels following intragastric administration
of insulin-loaded nanoparticles are shown in Fig. 4, and
pharmacokinetic parameters summarized in Table III. In-
creasing serum insulin levels were observed during the first 2
h following by lower continuous levels for 12 and 16 h with
doses of 50 and 100 IU/kg, respectively. The initial insulin
peak is probably related with the free insulin initially
released from nanoparticles, directly absorbed and then
eliminated from the blood by physiologic excretion. Then
subsequent continuous absorption resulting in a stable level
may be explained by continuous arrival of nanoparticles at
the absorptive sites, and sustained release of insulin from the
nanoparticles. Temporary retention of the mucoadhesive
nanoparticles in the upper intestine and late arrival to the
preferred sites for insulin absorption (35) and for nano-
particle uptake in the posterior ileum (13,40) may contribute
to the delayed prolonged insulinemia values. Adhering
nanoparticles remain at the insulin uptake sites for longer
than that of released insulin, and thus continue to release
insulin in a sustained manner. In addition, the extent of
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Fig. 4. Serum insulin levels after oral administration of insulin-
loaded nanoparticles in 50 (black triangles) and 100 (black squares)
IU/kg doses, and oral insulin solution at 50 IU/kg (white circles).
Data represents the mean T SD, n = 6 per group.
Table III. Pharmacokinetic Parameters for Serum Insulin Levels After Oral Administration of Insulin-Loaded Nanoparticles in Both 50 and
100 IU/kg Doses and Insulin Solution 50 IU/kg
Bioavailability (ng/mL h) Tmax (h) Cmax (ng/mL)
Insulin-loaded nanoparticles (50 IU/kg) 5.1 T 2.1a 2 0.59 T 0.30
Insulin-loaded nanoparticles (100 IU/kg) 9.5 T 3.7a 2 1.66 T 0.86
Oral Insulin solution (50 IU/kg) 2.1 T 0.9 1 0.20 T 0.10
Data represents the mean T SD, n = 6 per group
Tmax = time at maximum concentration of insulin in the blood, Cmax = maximum concentration of insulin in the blood
a Statistically significant differences from oral insulin solution control (p < 0.05). Bioavailability determined based on area under the curve
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Fig. 5. Confocal scanning microscopy images showing the association of FITC-insulin (green) to intestinal tissue (cell membranes in red). A
Control intestinal section showing the villi. B Inner apical intestinal section of rat treated with FITC-insulin oral solution. C Intestinal section
of rat treated with empty nanoparticles and Alexa Fluor colorant. D Inner apical intestinal section of rat with Peyer_s patches (PP) treated
with FITC-insulin nanoparticles. Peyer_s area show a deep green fluorescence. E Inner apical intestinal section of Peyer_s patch areas of rat
treated with FITC-insulin nanoparticles. F Inner apical upper intestinal section of rat treated with FITC-insulin nanoparticles. The three-
dimensional plan shows the internalization of labelled insulin. Grey lines indicate the plans were pictures were analyzed.
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release within the gastrointestinal track may be much less
than observed in vitro due to the viscous lumen and fasted
animal conditions.
The removal of insulin from the site of absorption may
be considered to be one of the barriers against free insulin
absorption. For this reason, increasing the retention time on
the mucosa due to adhesive particles can improve bioavail-
ability (41,42), which is concluded from Table III. It is also
possible that uptake of nanoparticles by Peyer_s patches in
the posterior ileum (2) can contribute to the maintenance of
insulinemia and consequent hypoglycaemic effect.
In general, bioavailability for reported oral insulin trials
has been low. For instance, pH-responsive poly(methacrylic-
g-ethylene glycol) hydrogel microparticles as oral insulin
delivery systems to diabetic rats resulted in bioavailability
less than 2.5% (37) and chitosan nanoparticles resulted in
bioavailability around 4% (33). Even for the new oral insulin
formulations under clinical evaluation, the bioavailability is
still limited (43). However, the bioavailability of 7% obtained
in the present work is considerably higher than that of
previous studies showing improved insulin absorption.
The mechanism and location of insulin absorption was
examined using FITC-insulin. Figure 5 shows confocal
images of intestinal sections after oral nanoparticle adminis-
tration. Fluorescence was observed throughout the ileum
tissue, both on the surface of the intestinal enterocytes and
on the M-cells. As suggested above, the retention of insulin
on the mucosa due to nanoparticle mucoadhesion and further
insulin absorption appears to be demonstrated by the
presence of FITC-insulin on the apical membrane of the
intestine 3 h after administration. Also the dense Peyer_s
patches region of the posterior ileum appeared labelled as
seen in Fig. 5D. Interaction of nanoparticles with M-cells of
the Peyer_s patches would suggest that nanoparticles were
concentrated on the follicle associate epithelium promoting
the absorption of the insulin. Peyer_s patches have previously
been associated with nanoparticle uptake (2,5,44), occurring
through adsorptive endocytosis (45). The location of the
fluorescent insulin may be seen below the surface layer of the
enterocytes inside the intestinal wall in the three-dimensional
section of Fig. 5E, F (lateral X–Z plan) suggesting that the
insulin is at various stages of internalization in the ileum. In
the negative control of rats treated with empty nanoparticles,
autofluoresce associated with the intestinal tissue was not
observed (Fig. 5C). After oral administration of FITC-insulin
solution, slight green fluorescence is visible associated with
the intestinal walls and its mucus, even after rinsing with
isotonic solution (Fig. 5B), possibly due to residual fluores-
cent products attached to the mucus associated with the
intestinal walls.
No one mechanism appears dominant in insulin uptake.
Besides providing protection from degradation in the gastro-
intestinal tract, the mucoadhesive (46) and absorption-
enhancing properties of Chit (19,47,48) and Alg (49) may
contribute to the high insulin concentration on the surface of
the intestinal wall and to its diffusion through the epithelium,
promoting insulin absorption. Furthermore, Chit is able to
reversibly alter tight junctions without provoking damage to
the cell membrane and without affecting the viability of
intestinal epithelial cells (33,50). Mucoadhesive nanoparticles
penetrating the mucous layer are able to prolong the
residence time and the insulin released can interact deeply
and permeate the intestinal barrier to the bloodstream.
Simultaneously, paracellular absorption and endocytosis
may be considered as synergic mechanisms for insulin
absorption (2). The paracellular pathway has been observed
to contribute to protein absorption since it has been shown
that most protein and polypeptide drugs diffuse through the
aqueous-filled tight junctional pathway due to their hydro-
philic nature (51). However, it is commonly identified as
limiting the absorption rate, due to the low surface area and
tightness of the junctions of the intercellular spaces (51).
Internalization of insulin via adsorptive endocytosis occur-
ring by non-specific interactions of nanoparticles with the cell
membrane (52) or through clathrin mediated interactions
(53) has been demonstrated as valid mechanisms for insulin
absorption. Also, the direct uptake of nanoparticles carrying
proteins by enterocytes is a limited but potential process, as
recently reviewed (2), contributing to the total amount of
absorbed insulin. Furthermore, the uptake of the nano-
particles by the M cells overlaying the Peyer_s patches can
contribute to a longer hypoglycaemic response (33,54).
CONCLUSION
Insulin-loaded alginate/chitosan nanoparticles produced
by ionotropic pre-gelation/polyelectrolyte complexation, pro-
vided markedly enhanced intestinal absorption of insulin
following oral administration. Nanoparticles lowered serum
glucose levels of streptozotocin-induced diabetic rats at
insulin doses of 50 and 100 IU/kg up to 59 and 55%
respectively, of their basal glucose level. The hypoglycemic
effect and insulinemia levels were significantly higher than
that obtained from oral insulin solution and physical mixture
of oral insulin and empty nanoparticles, revealing two to four
fold improvement of oral relative PA. In addition, the
physiological effect was observed for more than 18 h. The
mechanism of insulin absorption seems to be a combination
of both insulin internalization, probably through vesicular
structures in enterocytes and insulin-loaded nanoparticle
uptake by Peyer patches. Alginate/chitosan nanoparticles
appear promising as an oral delivery system for insulin and
potentially for other therapeutical proteins.
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